TR201907907T4 - Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. - Google Patents

Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. Download PDF

Info

Publication number
TR201907907T4
TR201907907T4 TR2019/07907T TR201907907T TR201907907T4 TR 201907907 T4 TR201907907 T4 TR 201907907T4 TR 2019/07907 T TR2019/07907 T TR 2019/07907T TR 201907907 T TR201907907 T TR 201907907T TR 201907907 T4 TR201907907 T4 TR 201907907T4
Authority
TR
Turkey
Prior art keywords
benralizumab
antigen
binding fragment
fev1
weeks
Prior art date
Application number
TR2019/07907T
Other languages
English (en)
Turkish (tr)
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR201907907T4 publication Critical patent/TR201907907T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
TR2019/07907T 2013-08-12 2014-08-07 Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. TR201907907T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12

Publications (1)

Publication Number Publication Date
TR201907907T4 true TR201907907T4 (tr) 2019-06-21

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07907T TR201907907T4 (tr) 2013-08-12 2014-08-07 Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3033104B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN105451769A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2866426T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE043497T2 (https=)
LT (2) LT3520811T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3520811T3 (https=)
PT (2) PT3520811T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT201900311T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素-5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
SMT202100152T1 (it) 2021-05-07
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
US9441046B2 (en) 2016-09-13
EP4636400A2 (en) 2025-10-22
CN111588849A (zh) 2020-08-28
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
CY1124399T1 (el) 2022-07-22
LT3520811T (lt) 2021-03-25
HK1225300A1 (en) 2017-09-08
CA2917603A1 (en) 2015-02-19
RS58711B1 (sr) 2019-06-28
KR102337599B1 (ko) 2021-12-10
EP4579236A2 (en) 2025-07-02
RU2016108809A3 (https=) 2018-06-18
SG11201600483QA (en) 2016-02-26
JP2020125304A (ja) 2020-08-20
HK1222559A1 (zh) 2017-07-07
HRP20190920T1 (hr) 2019-07-12
SMT201900311T1 (it) 2019-07-11
EP3875487A1 (en) 2021-09-08
JP2022120010A (ja) 2022-08-17
AU2014306959A1 (en) 2016-02-04
HUE043497T2 (hu) 2019-08-28
DK3033104T3 (da) 2019-06-17
RS61565B1 (sr) 2021-04-29
EP3033104A2 (en) 2016-06-22
CA2917603C (en) 2023-05-16
HRP20210406T1 (hr) 2021-04-30
EP3033104B1 (en) 2019-04-03
ES2866426T3 (es) 2021-10-19
JP6746496B2 (ja) 2020-08-26
JP2024129140A (ja) 2024-09-26
EP4636400A3 (en) 2025-12-24
MX2021003826A (es) 2021-05-27
SI3520811T1 (sl) 2021-04-30
SI3033104T1 (sl) 2019-06-28
DK3520811T3 (da) 2021-03-22
EP3033104A4 (en) 2017-03-22
ES2733602T3 (es) 2019-12-02
WO2015023507A2 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
EP4579236A3 (en) 2025-09-17
LT3033104T (lt) 2019-06-25
MX381102B (es) 2025-03-12
JP2016527325A (ja) 2016-09-08
WO2015023507A8 (en) 2015-09-24
PT3033104T (pt) 2019-06-27
PT3520811T (pt) 2021-03-15
AU2014306959B2 (en) 2019-11-21
RU2703568C2 (ru) 2019-10-21
HUE053627T2 (hu) 2021-07-28
KR20160043049A (ko) 2016-04-20
CN105451769A (zh) 2016-03-30
MX2016001384A (es) 2016-08-03
AU2020201277A1 (en) 2020-03-12
BR112016002317A2 (pt) 2017-12-12
US20150044203A1 (en) 2015-02-12
EP3520811B1 (en) 2020-12-30
BR112016002317A8 (pt) 2018-06-12
PL3033104T3 (pl) 2019-09-30
ME03403B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
TR201907907T4 (tr) Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab